RXi Pharmaceuticals (RXII) Earns Daily News Impact Score of 0.21
Media headlines about RXi Pharmaceuticals (NASDAQ:RXII) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.8986362004552 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Notable Volatile Movements: Extreme Networks, Inc., (NASDAQ: EXTR), RXi Pharmaceuticals Corporation, (NASDAQ … – Stocks In The News (press release) (tradingnewsnow.com)
- RXI Pharma (RXII) Reports Reports Positive Results with RXI-231 – StreetInsider.com (streetinsider.com)
- RXi Pharma: Consumer Testing Shows RXI-231’s Potential To Cut Skin Pigmentation (nasdaq.com)
- RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program (finance.yahoo.com)
- Hot Stock of the Day: RXi Pharmaceuticals Corporation (NASDAQ: RXII) – Alpha Beta Stock (alphabetastock.com)
Shares of RXi Pharmaceuticals (RXII) traded down $0.05 during mid-day trading on Friday, reaching $0.63. 412,600 shares of the company’s stock traded hands, compared to its average volume of 600,000. RXi Pharmaceuticals has a 52 week low of $0.32 and a 52 week high of $2.37.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter last year, the business earned ($0.34) earnings per share. sell-side analysts predict that RXi Pharmaceuticals will post -0.74 earnings per share for the current year.
In other news, insider Alexey Eliseev sold 176,800 shares of RXi Pharmaceuticals stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $0.54, for a total value of $95,472.00. Following the completion of the transaction, the insider now directly owns 1,100,931 shares of the company’s stock, valued at approximately $594,502.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.71% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/01/rxi-pharmaceuticals-rxii-earns-daily-news-impact-score-of-0-21.html.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.